Jackson J M, Fowler J F
University of Louisville, Division of Dermatology, Kentucky 40202, USA.
J Am Acad Dermatol. 1998 Jun;38(6 Pt 1):934-7. doi: 10.1016/s0190-9622(98)70589-4.
Methyldibromoglutaronitrile (MDGN) is a component of Euxyl K400, a preservative used in many skin care products in Europe. MDGN has been used in skin care products in the United States for the last 5 years. Contact allergy from MDGN has been reported from Europe.
The purpose of this study was to determine the frequency of MDGN as a sensitizer in patients undergoing routine patch testing.
We reviewed the results in 163 patients who underwent patch testing during a 4-month period to determine the number who had any reaction to MDGN at two different concentrations (0.2% and 0.5%). Tests were graded with the use of the North American Contact Dermatitis Group criteria (0 to 3+), and readings were performed at 48 and 96 hours (all positive reactions were evaluated at a follow-up visit or by telephone interview).
In the 4-month period, 45 of the 163 patients showed some reaction (+/- to 3+) at one or more readings. Of these, the results for 23 patients were considered to be irritant false-positive reactions; for 3 patients, the results were classified as uncertain; and for 19 patients, the results were classified as allergic. Of these, the results for eight patients were of definite relevance; the results for five patients were of probable relevance, and the results for six patients were of doubtful relevance to the problem condition. Other positive patch tests to a variety of allergens were frequently seen in persons positive to MDGN.
MDGN is a sensitizer in skin products and, with the increase of its use, should be considered in the patch test evaluation of patients with persistent dermatitis. Optimum patch test concentrations are yet to be determined.
甲基二溴戊二腈(MDGN)是优乐散K400的一种成分,优乐散K400是欧洲许多护肤品中使用的一种防腐剂。在过去5年中,MDGN已在美国的护肤品中使用。欧洲已有MDGN引起接触性过敏的报道。
本研究的目的是确定在接受常规斑贴试验的患者中,MDGN作为致敏原的频率。
我们回顾了163例在4个月期间接受斑贴试验的患者的结果,以确定在两种不同浓度(0.2%和0.5%)下对MDGN有任何反应的患者数量。使用北美接触性皮炎小组标准(0至3+)对试验进行分级,并在48小时和96小时进行读数(所有阳性反应均在随访就诊时或通过电话访谈进行评估)。
在4个月期间,163例患者中有45例在一次或多次读数时出现某种反应(+/-至3+)。其中,23例患者的结果被认为是刺激性假阳性反应;3例患者的结果被归类为不确定;19例患者的结果被归类为过敏。其中,8例患者的结果具有明确相关性;5例患者的结果可能具有相关性,6例患者的结果与问题状况的相关性存疑。在对MDGN呈阳性的患者中,经常还会看到对多种过敏原的其他阳性斑贴试验结果。
MDGN是皮肤产品中的一种致敏原,随着其使用的增加,在对持续性皮炎患者进行斑贴试验评估时应予以考虑。最佳斑贴试验浓度尚待确定。